<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877652</url>
  </required_header>
  <id_info>
    <org_study_id>CIS-D-02</org_study_id>
    <nct_id>NCT04877652</nct_id>
  </id_info>
  <brief_title>DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics</brief_title>
  <official_title>DR REGISTRY: Prospective Observational Study of Decongestion in Acute Heart Failure Patients With Insufficient Response to Diuretics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revamp Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revamp Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to observe and measure clinical outcomes, urine output, and safety&#xD;
      events occurring during standard medical treatment of ADHF patients deemed to have&#xD;
      insufficient diuretic response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>SAEs (including MACE) post enrollment based on CEC adjudication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Baseline [T=0] and 48 hours</time_frame>
    <description>Change in level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Output</measure>
    <time_frame>Baseline [T=0-12h] and through 24 hours [T=12-36h]</time_frame>
    <description>Change in the rate</description>
  </primary_outcome>
  <other_outcome>
    <measure>Dyspnea</measure>
    <time_frame>Baseline [T=0] and 48 hours</time_frame>
    <description>Change in dyspnea score using the Likert scale (score ranges from -3 to +3, higher score means better improvement)</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral Edema</measure>
    <time_frame>Baseline [T=0] and 48 hours</time_frame>
    <description>Change in score (ranges from none/0 to +4)</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>through follow-up period completion (up to 60 days)</time_frame>
    <description>Length of current hospitalization (resolution of acute heart failure condition)</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Failure Readmission</measure>
    <time_frame>Baseline through 30 days</time_frame>
    <description>Time to readmission due to HF, up to 30 days</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>ADHF patients</arm_group_label>
    <description>Patients with acute decompensated heart failure (ADHF) having insufficient response to diuretic therapy following a dose escalation protocol in keeping with AHA guidelines for the management of heart failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.</description>
    <arm_group_label>ADHF patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute Heart Failure Patients with Insufficient Response to Diuretics&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is &gt;18 and &lt; 85 years of age.&#xD;
&#xD;
          2. Subject is hospitalized with primary diagnosis of ADHF.&#xD;
&#xD;
          3. N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,600 pg/m or BNP≥400 pg/mL.&#xD;
&#xD;
          4. Evidence of fluid overload as indicated by 2 or more of the following criteria:&#xD;
&#xD;
               1. peripheral edema ≥ 2+&#xD;
&#xD;
               2. radiographic pulmonary edema or pleural effusion&#xD;
&#xD;
               3. enlarged liver or ascites&#xD;
&#xD;
               4. pulmonary rales or paroxysmal nocturnal dyspnea, or orthopnea&#xD;
&#xD;
               5. Jugular venous distention &gt; 7 cmH2O&#xD;
&#xD;
          5. Subject insufficiently responds to IV diuretic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systolic blood pressure &lt;90 mmHg at the time of screening.&#xD;
&#xD;
          2. Acute myocardial infarction or acute coronary syndrome or cardiogenic shock or pleural&#xD;
             synthesis within past 7 days or cardiovascular intervention within past 4 days.&#xD;
&#xD;
          3. Known LVEF &lt; 15% by echocardiography within 1 year prior to enrolment.&#xD;
&#xD;
          4. Complex congenital heart disease (e.g., Tetralogy of Fallot subjects, single ventricle&#xD;
             physiology).&#xD;
&#xD;
          5. Known active myocarditis, hypertrophic obstructive cardiomyopathy, constrictive&#xD;
             pericarditis or cardiac tamponade.&#xD;
&#xD;
          6. Severe Aortic valvular disorder (i.e., hemodynamically relevant valvular diseases such&#xD;
             as severe stenosis \severe regurgitation) or Severe mitral disease with planned&#xD;
             intervention.&#xD;
&#xD;
          7. Evidence of active systemic infection documented by either one of the following: fever&#xD;
             &gt;38°C/100°F, or ongoing uncontrolled infection (i.e., inflammatory parameters not&#xD;
             decreasing despite &gt; 48 hours of antibiotic treatment).&#xD;
&#xD;
          8. Moribund subject or subject with severe or deteriorating damage in more than 3&#xD;
             critical body systems, based on investigator's clinical judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sahar Boostenay</last_name>
    <phone>+972 54-462-1243</phone>
    <email>saharb153@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yael Shohat</last_name>
    <phone>+972 52-638-4749</phone>
    <email>YaelS@revampmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dolores Reynolds</last_name>
      <email>dtr2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>David Majure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parag Goyal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lovelyne Julien</last_name>
      <email>Lovelyne.Julien@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Noah Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adi Parihk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Privitera</last_name>
      <email>lp2183@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gabriel Sayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justin Fried, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Canral</last_name>
      <email>dcabral@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Sims, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandhya Murthy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pat Hendershot</last_name>
      <email>patricia.hendershot@chsli.org</email>
    </contact>
    <investigator>
      <last_name>Aman Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Jermyn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vidhya Ramachandran</last_name>
      <email>vir9086@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Kumudha Ramasubbu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shudhanshu Alishetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

